A Low Dose, Multi-drug Cocktail for the Treatment of Metastatic and Resistant Breast Cancers

Inventor(s):

    SUMMARY

    • An estimated 20-30% of breast cancer patients suffer from metastatic recurrence, which can be perpetuated by an overreliance on high doses of a single drug during initial treatment. In addition to promoting recurrence, ths treatment approach can also reduce drug sensitivity during relapse.
    • The Raf kinase inhibitor protein, RKIP, has previously been shown to block metastasis, but its in vivo kinase targets were unknown. The investigators used a combined mass spectroscopy and genomic approach to identify a RKIP-regulated network of target kinases involved in a metastatic signaling cascade. They then showed that the simultaneous inhibition of 4 kinases from the network mimicked the anti-metastatic effects of RKIP.
    • The invention is a method of treating metastatic cancer, using 4 different kinase inhibitors in the RKIP-network that target MEK1/2, p38 MAPK, JNK, and MLK 1/2/3/DLK. The invention drug cocktail can prevent metastasis, increase sensitivity in drug-resistant cancers, and offers a reduced risk of resistance over traditional monotherapy.
    • The investigators showed that the invention 4-drug cocktail stopped orthotopic and metastatic growth of triple negative breast cancer xenograft and syngeneic mouse models.

     

    FIGURE

    BoM1 C57/BL6 xenograft mice were treated for 4 weeks with either the full dose or half does of the 4-drug kinase inhibitor cocktail. Tumor growth is inhibited in mice treated with the invention 4 drug kinase inhibitor cocktail.

     

     

    ADVANTAGES

    ADVANTAGES

    • Can be used to treat triple negative breast cancer
    • Lower risk of drug resistant relapse than in treatment with monotherapies
    • Uses subtherapeutic dose of inhibitors

     

    APPLICATIONS

    • Oncology combination therapy

     

    PUBLICATIONS

     

     

    TECH DETAILS

    Published
    7/23/2019

    Reference ID
    18-T-043

    Have Questions?

    Michael Hinton

    Contact Michael Hinton, Manager, Technology Marketing, who can provide more detail about this technology, discuss the licensing process, and connect you with the inventor.

    This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.

    Accept
    [%Analytics%]